offline
RE: MeiraGTx Holdings plc
| 16.10.2021, 13:53 (Dieser Beitrag wurde zuletzt bearbeitet: 16.10.2021, 13:53 von boersenkater.)
BARRON´S
This Small Biotech Is Partnering With Johnson & Johnson. The Stock Could More Than Double.
Last Updated: Oct. 15, 2021 at 9:14 p.m.
ET First Published: Oct. 15, 2021 at 8:00 p.m. ET
Since the excitement of multibillion-dollar acquisitions of gene-therapy firms by Novartis and Roche Holding a few years ago, many gene-therapy stocks have sunk to small-cap valuations. Among them is MeiraGTx Holdings, shares of which fell from a 2019 peak of $30 to a recent $14, leaving its market capitalization below $600 million—and only a half-dozen analysts paying it heed.
That’s an opportunity for investors. MeiraGTx (ticker: MGTX) has several treatments in clinical trials, some of the industry’s best manufacturing centers, and a deep-pocketed partner in Johnson & Johnson (JNJ). And MeiraGTx says it has a technology that could revolutionize genetic medicine by regulating the artificial genes that gene-transfer therapies place in patients’ cells. MeiraGTx has been quietly working on that technology for six years and hasn’t revealed much data. But at today’s stock price, it could be a good time for investors with an appetite for risk to invest...............
https://www.marketwatch.com/articles/bio...=bigcharts
This Small Biotech Is Partnering With Johnson & Johnson. The Stock Could More Than Double.
Last Updated: Oct. 15, 2021 at 9:14 p.m.
ET First Published: Oct. 15, 2021 at 8:00 p.m. ET
Since the excitement of multibillion-dollar acquisitions of gene-therapy firms by Novartis and Roche Holding a few years ago, many gene-therapy stocks have sunk to small-cap valuations. Among them is MeiraGTx Holdings, shares of which fell from a 2019 peak of $30 to a recent $14, leaving its market capitalization below $600 million—and only a half-dozen analysts paying it heed.
That’s an opportunity for investors. MeiraGTx (ticker: MGTX) has several treatments in clinical trials, some of the industry’s best manufacturing centers, and a deep-pocketed partner in Johnson & Johnson (JNJ). And MeiraGTx says it has a technology that could revolutionize genetic medicine by regulating the artificial genes that gene-transfer therapies place in patients’ cells. MeiraGTx has been quietly working on that technology for six years and hasn’t revealed much data. But at today’s stock price, it could be a good time for investors with an appetite for risk to invest...............
https://www.marketwatch.com/articles/bio...=bigcharts
__________________
